Mason Archival Repository Service

Characterizing the Effect of Bortezomib on Rift Valley Fever Virus Multiplication

Show simple item record

dc.contributor.advisor Narayanan, Aarthi
dc.contributor.author Keck, Forrest David
dc.creator Keck, Forrest David
dc.date 2015-04-22
dc.date.accessioned 2015-08-13T13:44:30Z
dc.date.available 2015-10-28T04:23:01Z
dc.date.issued 2015-08-13
dc.identifier.uri https://hdl.handle.net/1920/9736
dc.description This work was embargoed by the author and will not be publicly available until October 2015. en_US
dc.description.abstract This thesis investigates the FDA-approved cancer drug Bortezomib; characterizing its use as a novel application in Bunyavirus antiviral therapy. Rift Valley Fever virus (RVFV) belongs to the family Bunyaviridae and is a known cause of epizootics and epidemics in Africa and the Middle East. With no FDA approved therapeutics available to treat RVFV infection, understanding the interactions between the virus and the infected host is crucial to developing novel therapeutic strategies. Here, we investigated the requirement of the ubiquitin-proteasome system (UPS) for the establishment of a productive RVFV infection. It was previously shown that the UPS plays a central role in RVFV multiplication involving degradation of PKR and p62 subunit of TFIIH. Using the FDA-approved proteasomal inhibitor Bortezomib, we observed robust inhibition of intracellular and extracellular viral loads. Bortezomib treatment did not affect the nuclear/cytoplasmic distribution of the non-structural protein NSs; however, the ability of NSs to form nuclear filaments was abolished as a result of Bortezomib treatment. In silico ubiquitination prediction analysis predicted that known NSs interactors (SAP30, YY1, and mSin3A) have multiple putative ubiquitination sites, while NSs itself was not predicted to be ubiquitinated. Immunoprecipitation studies indicated a decrease in interaction between SAP30 – NSs, and mSin3A – NSs in the context of Bortezomib treatment. This decrease in association between SAP30 - NSs also correlated with a decrease in the ubiquitination status of SAP30 with Bortezomib treatment. Bortezomib treatment, however; resulted in increased ubiquitination of mSin3A, suggesting that Bortezomib dynamically affects the ubiquitination status of host proteins that interact with NSs. Finally, we observed that expression of interferon beta (IFN-β) was increased in Bortezomib treated cells which indicated that the cellular antiviral mechanism was revived as a result of treatment and may contribute to control of viral multiplication.
dc.language.iso en en_US
dc.subject Rift Valley Fever Virus en_US
dc.subject Ubiquitin proteasome system en_US
dc.subject NSs en_US
dc.subject SAP30 en_US
dc.subject mSin3A en_US
dc.subject IFN-B en_US
dc.title Characterizing the Effect of Bortezomib on Rift Valley Fever Virus Multiplication en_US
dc.type Thesis en
thesis.degree.name Master of Science in Biology en_US
thesis.degree.level Master's en
thesis.degree.discipline Biology en
thesis.degree.grantor George Mason University en


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search MARS


Browse

My Account

Statistics